Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial

[1]  I. Bruce,et al.  Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial , 2022, Lupus Science & Medicine.

[2]  C. Gordon,et al.  Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus , 2021, Annals of Internal Medicine.

[3]  B. Diamond,et al.  Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. , 2021, The Journal of clinical investigation.

[4]  I. Bruce,et al.  Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment , 2020, RMD Open.

[5]  A. Bengtsson,et al.  Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus , 2020, International journal of molecular sciences.

[6]  G. Schett,et al.  IgA subclasses have different effector functions associated with distinct glycosylation profiles , 2020, Nature Communications.

[7]  R. Cummings,et al.  Human IgA binds a diverse array of commensal bacteria , 2019, The Journal of experimental medicine.

[8]  C. Gordon,et al.  Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial , 2019, BMJ Open.

[9]  I. Gunnarsson,et al.  High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus , 2019, Arthritis Research & Therapy.

[10]  Frauke Degenhardt,et al.  Evaluation of variable selection methods for random forests and omics data sets , 2017, Briefings Bioinform..

[11]  M. Wittmann,et al.  A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features , 2018, Scientific Reports.

[12]  T. Rabelink,et al.  FRI0330 Rituximab therapy in sle: early retreatment is associated with lower disease activity and a reduction in corticosteroid use , 2018, Journal of autoimmunity.

[13]  R. V. van Neerven,et al.  BAFF augments IgA2 and IL‐10 production by TLR7/8 stimulated total peripheral blood B cells , 2017, European journal of immunology.

[14]  B. Rudolph,et al.  Plasmablasts With a Mucosal Phenotype Contribute to Plasmacytosis in Systemic Lupus Erythematosus , 2017, Arthritis & rheumatology.

[15]  F. Abd-Allah,et al.  FRI0309 Type I Interferon Activity Is Associated with Mucocutaneous but Not Musculoskeletal Disease Activity in Systemic Lupus Erythematosus , 2016 .

[16]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[17]  Jong Wha J. Joo,et al.  Multiple testing correction in linear mixed models , 2016, Genome Biology.

[18]  X. Zhang,et al.  Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production , 2015, Lupus.

[19]  W. Rigby,et al.  Induction of Interleukin‐6 Production by Rituximab in Human B Cells , 2014, Arthritis & rheumatology.

[20]  P. Emery,et al.  Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy , 2014, Annals of the rheumatic diseases.

[21]  D. Isenberg,et al.  Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. , 2013, Arthritis and rheumatism.

[22]  L. Punzi,et al.  Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease , 2013, PloS one.

[23]  V. Pascual,et al.  Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation , 2012, The Journal of experimental medicine.

[24]  M. Petri,et al.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response , 2012, Annals of the rheumatic diseases.

[25]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[26]  K. McCoy,et al.  Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. , 2011, The Journal of clinical investigation.

[27]  I. Bruce,et al.  An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA , 2010, Annals of the rheumatic diseases.

[28]  Witold R. Rudnicki,et al.  Feature Selection with the Boruta Package , 2010 .

[29]  I. Bruce,et al.  Numerical scoring for the BILAG-2004 index , 2010, Rheumatology.

[30]  A. Kantele,et al.  Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body Fluids , 2010, Clinical and Vaccine Immunology.

[31]  A. Plebani,et al.  Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. , 2007, Immunity.

[32]  H. Peter,et al.  Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus , 1998, Rheumatology International.